As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Hologic (HOLX) with a Peer Perform rating and no price target The Diagnostics & Med Tech company caters to the healthcare and clinical end markets and the firm calls the company “an intriguing asset with a strong management team and unique portfolio.” However, while material downside risk is likely limited from here, the firm feels near term respiratory headwinds and saline shortages likely make expectations too high and calls it “best to stay on the sidelines for now.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic initiated with a Peer Perform at Wolfe Research
- Cervical cancer recommendations lift ‘minor overhang’ on Hologic, says Leerink
- USPSTF draft guidance on cervical cancer positive for Hologic, says BTIG
- Hologic Expands Board with Martin Madaus Appointment
- Hologic initiated with a Hold at Jefferies